Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia a

Blood

Volumn 124, Issue 15, 2014, Pages 2333-2336

  Castaman, Giancarlo ^a,b   Fijnvandraat, Karin ^c  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; ANTIBODY;

AMINO ACID SUBSTITUTION; DRUG SAFETY; HEMOPHILIA A; HUMAN; HYPONATREMIA; IMMUNOLOGICAL TOLERANCE; MILD HEMOPHILIA A; MISSENSE MUTATION; REVIEW; SUBSTITUTION THERAPY; ANIMAL; IMMUNOLOGY; RISK FACTOR;

ANIMALS; ANTIBODIES; HEMOPHILIA A; HUMANS; RISK FACTORS;

EID: 84907603719     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-546127     Document Type: Review

References (34)

1. Arnold DM, Julian JA, Walker IR; Association of Hemophilia Clinic Directors of Canada. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood. 2006;108(2):460-464.
2. Darby SC, Kan SW, Spooner RJ, et al, for the Haemophilia Centre Doctors' Organisation. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110(3):815-825.
3. Tagliaferri A, Di Perna C, Riccardi F, Pattacini C, Rivolta GF, Franchini M. The natural history of mild haemophilia: a 30-year single centre experience. Haemophilia. 2012;18(2):166-174.
4. Fijnvandraat K, Cnossen MH, Leebeek FWG, Peters M. Diagnosis and management of haemophilia. BMJ. 2012;344:e2707.
5. Peerlinck K, Jacquemin M. Mild haemophilia: a disease with many faces and many unexpected pitfalls. Haemophilia. 2010;16(Suppl 5):100-106.
6. Kumar R, Stain AM, Hilliard P, Carcao M. Consequences of delayed therapy for sports-related bleeds in patients with mild-to-moderate haemophilia and type 3 von Willebrand's disease not on prophylaxis. Haemophilia. 2013;19(4):e264-e267.
7. d'Oiron R, Pipe SW, Jacquemin M. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development. Haemophilia. 2008;14(Suppl 3):138-146.
8. Eckhardt CL, van Velzen AS, Peters M, et al; INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122(11):1954-1962.
9. Structural Immunology Group, University College London. Factor VIII Variant Database. http://hadb.org.uk. Accessed August 22, 2014.
10. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia. 1998;4(4):558-563.
11. +T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood. 2003;101(4):1351-1358.
12. James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost. 2007;5(12):2399-2407.
13. Schwaab R, Pavlova A, Albert T, Caspers M, Oldenburg J. Significance of F8 missense mutations with respect to inhibitor formation. Thromb Haemost. 2013;109(3):464-470.
14. Santoro RC, Prejano S, Morgione S, Iannaccaro P. Risk of inhibitor development in non severe hemophilia A patients with a single mutation [e-letter]. Blood. 25 October 2013.
15. Hay CR, Ludlam CA, Colvin BT, et al; UK Haemophilia Centre Directors Organisation. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Thromb Haemost. 1998;79(4):762-766.
16. Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost. 2003;1(6):1228-1236.
17. Mauser-Bunschoten EP, Den Uijl IEDM, Schutgens REG, Roosendaal G, Fischer K. Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia. 2012;18(2):263-267.
18. Eckhardt CL, Menke LA, van Ommen CH, et al. Intensive peri-operative use of factor VIII and the Arg593 - >Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost. 2009;7(6):930-937.
19. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Thromb Haemost. 1995;74(2):619-621.
20. Peerlinck K, Jacquemin MG, Arnout J, et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood. 1999;93(7):2267-2273.
21. Carcao M, St Louis J, Poon MC, et al; Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia. 2006;12(1):7-18.
22. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90(7):2515-2521.
23. Castaman G. Desmopressin for the treatment of haemophilia. Haemophilia. 2008;14(Suppl 1):15-20.
24. Castaman G, Mancuso ME, Giacomelli SH, et al. Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A. J Thromb Haemost. 2009;7(11):1824-1831.
25. Stoof SCM, Sanders YV, Petrij F, et al. Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A. Thromb Haemost. 2013;109(3):440-449.
26. Nance D, Fletcher SN, Bolgiano DC, Thompson AR, Josephson NC, Konkle BA. Factor VIII mutation and desmopressin-responsiveness in 62 patients with mild haemophilia A. Haemophilia. 2013;19(5):720-726.
27. Seary ME, Feldman D, Carcao MD. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype. Haemophilia. 2012;18(1):50-55.
28. Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol. 2000;109(4):865-869.
29. Revel-Vilk S, Blanchette VS, Sparling C, Stain AM, Carcao MD. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol. 2002;117(4):947-951.
30. Castaman G, Tosetto A, Rodeghiero F. Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance. J Thromb Haemost. 2009;7(Suppl 1):71-74.
31. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol. 1992;82(1):87-93.
32. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol. 1989;31(3):199-202.
33. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med. 1988;318(2):121.
34. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol. 1988;28(1):63-65.